Buspirone May Improve Sexual Function, Not Increase Sex Drive Directly
Buspirone (Buspar) does not inherently increase libido or sex drive in most people, but it may improve sexual function by reversing sexual side effects caused by other antidepressants, particularly SSRIs. 1, 2, 1
Clinical Context and Evidence
Off-Label Use for Sexual Dysfunction
The most recent NCCN guidelines (2024) recognize buspirone as an off-label option for hypoactive sexual desire disorder (HSDD), particularly in cancer survivors, though the evidence base is limited to small trials in non-cancer populations 1. The 2017 NCCN guidelines similarly positioned buspirone alongside bupropion as reasonable options for survivors with low desire, libido, or intimacy issues, despite acknowledging limited safety and efficacy data 2.
Mechanism: Reversal of SSRI-Induced Sexual Dysfunction
The key distinction is that buspirone appears to counteract SSRI-induced sexual side effects rather than directly enhancing libido. A placebo-controlled study of 117 depressed patients on SSRIs (citalopram or paroxetine) found that approximately 58% of buspirone-treated subjects reported improvement in sexual function versus 30% with placebo, with effects appearing within the first week 3. This suggests buspirone's benefit is primarily in reversing medication-induced sexual dysfunction, not enhancing baseline sexual function.
Evidence in Anxiety Patients
One small study (n=10) in patients with generalized anxiety disorder showed normalization of sexual function in 8 of 10 patients after 4 weeks of buspirone treatment 4. However, this likely reflects improvement in anxiety-related sexual dysfunction rather than direct libido enhancement.
FDA-Approved Indications and Safety Profile
The FDA has not approved buspirone for sexual dysfunction—it is indicated only for anxiety disorders 5. The FDA drug label specifically lists both decreased and increased libido as infrequent adverse events (occurring in 1/100 to 1/1000 patients), along with rare reports of delayed ejaculation and impotence 5. This bidirectional effect on libido underscores that buspirone does not reliably increase sex drive.
Important Caveats and Safety Concerns
Potential for Problematic Use
Recent pharmacovigilance data from the FAERS database (2006-2025) identified concerning signals including drug abuse (n=43), intentional overdose (n=30), and increased drug levels (n=17), suggesting potential for misuse, particularly in individuals with substance use disorder history 6. A 2025 scoping review documented cases of buspirone insufflation for sedative effects among individuals with incarceration or substance use disorder histories 7.
Contraindications and Drug Interactions
- Do not combine with MAOIs (contraindicated due to serotonin syndrome risk) 5
- Avoid within 14 days of MAOI discontinuation
- Use caution with other serotonergic agents
- May cause restlessness, akathisia, or dopaminergic effects in some patients 5
Clinical Algorithm for Sexual Dysfunction
When considering buspirone for sexual concerns:
Identify the underlying cause:
- SSRI-induced sexual dysfunction → Buspirone may help (off-label, moderate evidence)
- Primary HSDD without medication cause → Consider FDA-approved options first (flibanserin for premenopausal women, bremelanotide) 1
- Anxiety-related sexual dysfunction → Treat anxiety; sexual function may improve secondarily
Dosing considerations:
Monitor for:
- Improvement in sexual function (not necessarily increased libido)
- Common side effects: dizziness, nausea, headache, nervousness 5
- Paradoxical effects on libido (can decrease in some patients)
Bottom line: Buspirone is not a reliable libido enhancer but may be useful as an off-label adjunct to reverse SSRI-induced sexual dysfunction. For primary low sexual desire, FDA-approved agents like flibanserin or bremelanotide are more appropriate first-line options in suitable candidates.